Der Report
Tiefgehende Einblicke in Unternehmensfinanzierung, Wachstumsstrategien und Markterkenntnisse der innovativsten Unternehmen der Welt
8,021 Berichte und es werden mehr
Foundation Medicine Raises $100M in Series D
Foundation Medicine, a Biotech company based in Cambridge, MA, has raised $100M in Series D at a $1B valuation led by Third Rock Ventures, Google Ventures.
Foundation Medicine raises $100M Series D at $1B valuation
Foundation Medicine raises $100M in Series D at $1B valuation. Genomic profiling for cancer treatment...
Parabilis Medicines Raises $305M Series F | Precision Medicine Platform
Biotech company Parabilis Medicines secures $305 million Series F for precision medicine development.
Homology Medicines raises $127M Series C at $1B valuation
Homology Medicines raises $127M in Series C at $1B valuation. Genetic medicines platform...
Editas Medicine raises $118M Follow-on Offering at $1.8B valuation
Editas Medicine raises $118M in Follow-on Offering at $1.8B valuation. Genome editing medicines...
Homology Medicines Raises $127M in Series C
Homology Medicines, a Biotech company based in 45 Wiggins Avenue, Bedford, MA 01730, has raised $127M in Series C at a $1B valuation led by ARCH Venture Partners, Temasek Holdings, Fidelity, Deerfield Management.
Editas Medicine Raises $118M in Follow-on Offering
Editas Medicine, a Biotech company based in 11 Hurley Street, Cambridge, MA 02141, has raised $118M in Follow-on Offering at a $1.8B valuation led by Polaris Partners, Flagship Pioneering, Third Rock Ventures, Google Ventures.
Prime Medicine Raises $315M in Series B
Prime Medicine, a Biotech company based in 800 Boylston Street, Boston, MA 02199, has raised $315M in Series B at a $1.85B valuation led by GV, F-Prime Capital, Westlake Village BioPartners, ARCH Venture Partners, Deerfield Management.
Prime Medicine raises $315M Series B at $1.85B valuation
Prime Medicine raises $315M in Series B at $1.85B valuation. Prime editing gene therapy...
9 Berichte angezeigt • Seite 1 • Kategorie: all
Bleiben Sie dem Markt voraus
Erhalten Sie wöchentliche Insights direkt in Ihren Posteingang. Kein Spam, nur Intelligence.